Professor, Hematology and Medical Oncology, Emory University School of Medicine
Oncology
Dr. Amelia A. Langston, MD
|
|
Give Review
Amelia Langston is an expert in the field of Oncology. She went to Washington University School of Medicine in St. Louis. She over the years received 1 awards: "Regional Top Doctor". Amelia A. Langston, MD is a published physician. She published 44 publications, including: 'Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.' She accepts all Medicare patients.
Publications
- Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal Disease.
- A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgki...
- Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and Immune reconstitution analysis.
- Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with Neutropenia.
- A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.
- Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell Lymphoma.
- Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem Cell transplantation.
- Similar Survival for Patients Undergoing Reduced-Intensity Total Body Irradiation (TBI) Versus Myeloablative TBI as Conditioning for Allogeneic Transplant in Acute Leu...
- In vivo T cell costimulation blockade with abatacept for Acute graft-versus-host disease prevention: a first-in-disease trial.
- Consolidation and maintenance therapy with lenalidomide, bortezomib, dexamethasone (RVD) in high-risk Myeloma patients.
- Advances in hematopoietic stem cell transplantation in chronic myeloid Leukemia.
- Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic Cell transplants from partially mismatched unrelated donors.
- Temporal changes in plerixafor administration and hematopoietic stem Cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
- Bortezomib-containing induction regimens in transplant-eligible Myeloma patients: A meta-analysis of phase 3 randomized clinical trials.
- Epsilon aminocaproic acid prevents bleeding in severely Thrombocytopenic patients with hematological malignancies.
- Inherited predisposition to multiple Myeloma.
- Graft-versus-host disease and Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
- Mobilization of Hematopoietic Progenitors from Normal Donors Using the Combination of Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulati...
- Antimicrobial prophylaxis and outpatient management of Fever and Neutropenia in adults treated for malignancy: american society of clinical oncology clinical practice ...
- A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with Lymphoma.
- Rifaximin for Preventing Acute Graft-Versus-Host Disease: Impact on Plasma Markers of Inflammation and T-cell Activation.
- Early clearance of peripheral blood blasts predicts response to induction chemotherapy in Acute myeloid leukemia.
- Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with Graft-versus-host disease.
- A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-Cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
- A cluster of mucorMycosis infections in hematology patients: challenges in investigation and control of invasive mold infections in high-risk patient populations.
- The economic costs to United States hospitals of invasive fungal infections in transplant patients.
- Nonmyeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high risk Acute lymphoblastic leukemia.
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
- Receiver operating characteristic curve analysis of circulating blood dendritic Cell precursors and T Cells predicts response to extracorporeal photopheresis in patien...
- A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple Myeloma: a dose- and schedule-finding study.
- Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with Acute myeloid leukemia.
- Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients.
- Five-year follow-up of patients with advanced chronic lymphocytic Leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
- Extended mycophenolate mofetil and shortened cyclosporine failed to reduce Graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloab...
- Allogeneic marrow transplantation in patients with severe Systemic sclerosis: resolution of dermal fibrosis.
- Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor Cell transplantation for multiple myeloma.
- Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear Cell transplantation after nonmyeloablative conditioning: the effect of po...
- Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell Lymphoma.
- Facilitating T-cell Immune reconstitution after haploidentical transplantation in adults.
- Update on Myelodysplastic syndromes: new approaches to classification and therapy.
- Update in Acute leukemia 2003: a risk adapted approach to Acute myeloblastic leukemia in adults.
- Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor Cell transplantation.
- Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor Cell transplantation.
Schools
Washington University St Louis
Duke University
University Washington
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Breast Cancer
- Central Nervous System Lymphoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Duke University Hospital -
Washington University School of Medicine in St. Louis
Hospital
-
Emory University Hospital -
Emory University Hospital Midtown -
Grady Memorial Hospital
Drug Facts
| NPI NUMBER | 1346357019 | |
| NPPES Provider LastName | LANGSTON | |
| NPPES Provider FirstName | AMELIA | |
| NPPES Provider ZIPCode | 303221013 | |
| NPPES Provider State | GA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1445.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 159.0 | |
| Percent Opioid Claims | 11.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1346357019 |
| Last Name Of The Provider | LANGSTON |
| First Name Of The Provider | AMELIA |
| View All |
Similar Doctors
|
|
Dr. Barry M. Yaffe, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Torey B. Clark, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arielle C. Lutterman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rajni Sinha, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Navneet Dhillon, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Leroy Fass, MD
This Doctor is OpenDoctor Recommended.
|